AstraZeneca vaccine, thrombosis risk and second dose in Italy. The AIFA specifies that Vaxzevria is safe and invites you to complete the vaccination which represents the best strategy to combat Covid and guarantees the best level of protection from the disease. Read also Aifa: “On safety at under 60 uncertainty margins” “The safety of the administration of the AstraZeneca vaccine (Vaxzevria) in subjects under the age of 60 remains an open topic, and on which there are margins of uncertainty”. Despite these uncertainties, regarding the second dose for the ‘under 60’ vaccinated with AstraZeneca, the Aifa Hemostasis and Thrombosis Working Group believes that “the completion of the vaccination schedule represents the strategy to combat the spread of the Sars-Cov-2 virus. which guarantees the best level of protection “. This is established by the in-depth document of the Hemostasis and Thrombosis Working Group of experts in coagulation pathologies on post-Covid thromboembolic complications with the AstraZeneca and Johnson & Johnson vaccines, appointed by the AIFA. Experts answer 10 questions, the last one concerns the existence of a rationale for deciding what to do with the second dose for subjects under 60 who have already taken the first dose of Vaxzevria.